|One Franklin Pkwy , San Mateo, CA 94403|
|Fund Manager||Team Managed|
Capital appreciation. Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The Fund predominantly invests in equity securities. For the Fundâ€™s investment purposes, a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the companyâ€™s most recent fiscal year. Discovery research firms are in the early stages of drug research. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes.
|Asset Type||% Of Allocation|
|Total Net Assets||17.05 M|
|Criteria||3 Years||5 Years||10 Years|
|Minimum Initial IRA||$0|
|Timeframe||Average Annual Current Performance Monthly As Of 08/31/2021||Average Annual Current Performance Quarterly As Of 06/30/2021||Avg Annual Current Performance Monthly As Of 08/31/2021||Avg Annual Current Performance Quarterly As Of 06/30/2021|
|Life Of Fund||
|Symbol||Company Name||% Of Assets|
|GILD||GILEAD SCIENCES INC||6.08%|
|VRTX||VERTEX PHARMACEUTICALS INC||4.64%|
|HZNP||HORIZON THERAPEUTICS PUBLIC||3.57%|
|IOVA||IOVANCE BIOTHERAPEUTICS INC||3.03%|
|MRTX||MIRATI THERAPEUTICS INC||2.54%|
Join the Action Alerts PLUS Community today!
'Our fundamental thesis remains unchanged, and we see the sell-off as an opportunity to buy the dip,' said JPMorgan strategist Kolanovic.
Shell has signed an agreement to sell its Permian basin assets to ConocoPhillips for $9.5 billion cash.